Innate immune cells in the bladder and bone marrow

Innate immune cells in the bladder and bone marrow refer to a heterogeneous population of immune responders, including macrophages, neutrophils, monocytes, and natural killer (NK) cells, that coordinate the first line of defense in the urinary tract and are maintained by the hematopoietic reservoir in the bone marrow. In the bladder, these cells are critical for detecting uropathogens and responding to urothelial malignancies through the release of pro-inflammatory cytokines and direct phagocytic activity (Nature Reviews Urology, 2019). The bone marrow serves as the primary site for the production and mobilization of these cells, which can be recruited to the bladder during acute injury or infection (Journal of Experimental Medicine, 2020). A primary clinical application involving these cells is the use of intravesical Bacillus Calmette-Guérin (BCG) therapy for non-muscle invasive bladder cancer, which relies on the recruitment and activation of innate cells to eliminate tumor cells (PubMed, PMID: 28967331). However, because this term describes a broad cellular system and anatomical locations rather than a specific molecular entity like a receptor or enzyme, it is not classified as a canonical therapeutic target. Instead, it represents a complex physiological environment that is modulated by various immunotherapies to enhance regional and systemic immunity.

Other names

Innate immunity of the urotheliumMyeloid cells of the urinary tract and hematopoietic systemBladder-resident innate immune system

Drugs typically modulate these cell populations by stimulating pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), to induce a localized inflammatory response or by mobilizing progenitor cells from the bone marrow to the site of infection or malignancy.